Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Pharma Mar in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $68.50.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Pharma Mar. This rating has held steady since October 2021, when it changed from a Hold consensus rating.
Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It operates through the following segments: Oncology, Diagnostics, and RNAi. The Oncology segment focuses to the group undertakings whose object is to research, develop, and market anti-tumour drugs. The Diagnostics segment focuses in the development and marketing of diagnostic kits. The RNAi segment develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was founded by José Maria Fernández de Sousa-Faro on April 30, 1986 and is headquartered in Colmenar Viejo, Spain.
Read More